<DOC>
	<DOCNO>NCT03022409</DOCNO>
	<brief_summary>This biomarker window basket study design intent assess effect different agent tumour tissue peripheral sample inform optimal combination DDR agent immuno-oncology ( IO ) therapies suitable sequence relative timing therapy . In first instance 2 DDR agent assess monotherapy . Based emerge data additional arm may incorporate evaluate DDR agent and/or DDR immunotherapy agent combination series . The primary objective study investigate immune activation due DDR inhibition monitor induction TH1/IFNg response tumour patient treat study investigational agent ( )</brief_summary>
	<brief_title>A Study Investigate Biomarker Effects Pre-Surgical Treatment With DNA Damage Repair ( DDR ) Agents Patients With Head Neck Squamous Cell Carcinoma ( HNSCC )</brief_title>
	<detailed_description>Patients dose minimum 10 day investigational agent . Surgery scheduled time day 11 day 21 ( margin + 3 day allow unexpected event ) must occur within 0 3 day follow three consecutive investigational drug product administration day . During treatment period , safety assessment must complete least weekly . The Follow Up visit complete surgical resection complete aligned standard post-surgery follow visit . If follow visit occur prior 30 day final dose , visit telephone call must conduct follow AE resolution late emerge AEs . Patients receive investigational agent ( ) minimum 10 day maximum 3 week . The duration dose investigational agent dependent timing plan surgery .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Olaparib</mesh_term>
	<criteria>Provision sign date , write informed consent prior study specific procedure , sample analysis ; include access archival tumour tissue ( diagnostic and/or recent sample ) Aged least 18 year Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 deterioration previous 2 week estimate life expectancy great 12 week Newly diagnose , treatment naive , HNSCC suitable surgical resection plan radiotherapy and/or chemotherapy surgery Females must use adequate contraceptive measure , must breast feeding must negative pregnancy test prior start dose childbearing potential must evidence nonchildbearing potential For duration study 1 week last study drug administration , sexually active male patient must willing use barrier contraception i.e. , condom sexual partner No previous cancer treatment cytotoxic agent malignancy Provision genetics research inform consent Involvement planning and/or conduct study Previous enrolment present study Participation another clinical study investigational product last 21 day 5 halflives investigational product , whichever longer With exception alopecia , unresolved toxicity prior therapy ≥ Common Terminology Criteria Adverse Events ( CTCAE ) grade 2 Spinal cord compression brain metastasis unless asymptomatic , stable require steroid least 4 week prior start study treatment Receiving , receive four week prior first dose , cytotoxic treatment malignancy Receiving , receive week prior first dose , corticosteroid reason Hypersensitivity investigational agent test , excipient product Treatment small molecule investigational medicinal product ( IMP ) within 28 day prior first dose Receiving , receive , concomitant medication , herbal supplement and/or food significantly modulate CYP3A4 inhibitor moderate CYP3A inhibitor , strong CYP3A inducer moderate CYP3A inducer Impaired hepatic renal function , inadequate bone marrow reserve organ function , Cardiac dysfunction Any follow cardiac criterion : Mean rest correct QTc interval use Fridericia formula ( QTcF ) great 450 msec/male great 470 msec/female congenital long QT syndrome Any clinically important abnormality rhythm , conduction morphology rest ECG ( e.g. , complete leave bundle branch block , third degree heart block ) Any factor increase risk QTc prolongation risk arrhythmic event heart failure , hypokalaemia , congenital long QT syndrome , immediate family history long QT syndrome unexplained sudden death 40 year age Patients risk brain perfusion problem , e.g. , carotid stenosis • Uncontrolled hypertension require clinical intervention Any malignancy active treat within past three year , exception cervical intraepithelial neoplasia nonmelanoma skin cancer Refractory nausea vomiting , chronic gastrointestinal disease previous significant bowel resection , clinically significant sequela would preclude adequate absorption investigational agent test Uncontrolled seizure Patients unable swallow orally administer medication patient gastrointestinal disorder likely interfere absorption study medication Concurrent severe and/or uncontrolled medical condition psychiatric condition Any contraindication combination anticancer agent per local prescribe information Serious active infection time enrolment , another serious underlie medical condition would impair ability patient receive study treatment Any previous treatment DDR agent , include investigational agent Patients myelodysplastic syndrome/acute myeloid leukaemia feature suggestive MDS/AML Patients consider poor medical risk due serious , uncontrolled medical disorder , nonmalignant systemic disease active , uncontrolled infection Immunocompromised patient Patients know hypersensitivity investigational agent excipients product Patients know active hepatitis ( i.e . Hepatitis B C ) Previous allogenic bone marrow transplant double umbilical cord blood transplantation ( dUCBT ) Nonleukocyte deplete whole blood transfusion within 120 day date patient 's start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>130 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Treatment naïve</keyword>
	<keyword>Head Neck Squamous Cell Carcinoma ( HNSCC )</keyword>
	<keyword>DNA Damage Repair ( DDR )</keyword>
</DOC>